Edwards Lifesciences Corporation (EW)
US — Healthcare Sector
Automate Your Wheel Strategy on EW
With Tiblio's Option Bot, you can configure your own wheel strategy including EW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EW
- Rev/Share 10.0629
- Book/Share 17.4534
- PB 4.9148
- Debt/Equity 0.0686
- CurrentRatio 4.0043
- ROIC 0.1135
- MktCap 50365469403.0
- FreeCF/Share 1.3754
- PFCF 62.628
- PE 36.7575
- Debt/Assets 0.0528
- DivYield 0
- ROE 0.1335
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | EW | Raymond James | Market Perform | Outperform | -- | $96 | Nov. 3, 2025 |
| Upgrade | EW | Jefferies | Hold | Buy | -- | $98 | Oct. 29, 2025 |
| Upgrade | EW | Wolfe Research | Underperform | Peer Perform | -- | -- | Oct. 29, 2025 |
| Downgrade | EW | Oppenheimer | Outperform | Perform | -- | -- | Oct. 8, 2025 |
| Upgrade | EW | Evercore ISI | In-line | Outperform | -- | $88 | Oct. 7, 2025 |
| Upgrade | EW | BTIG Research | Neutral | Buy | -- | $100 | July 29, 2025 |
| Upgrade | EW | Piper Sandler | Neutral | Overweight | -- | $80 | April 24, 2025 |
| Upgrade | EW | Stifel | Hold | Buy | $75 | $90 | Jan. 30, 2025 |
| Downgrade | EW | Wolfe Research | Peer Perform | Underperform | -- | $60 | Jan. 16, 2025 |
| Upgrade | EW | BofA Securities | Neutral | Buy | -- | -- | Dec. 16, 2024 |
News
Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics
EW
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
About Edwards Lifesciences Corporation (EW)
- IPO Date 2000-03-27
- Website https://www.edwards.com
- Industry Medical - Devices
- CEO Bernard J. Zovighian
- Employees 15800
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.